Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.61 |
| ▸ | CASR | P41180 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412142 | 1.00 | CFTR (0.61) | CFTRCASRPOLBKDM4EMEN1 | |
| SCHEMBL29411951 | 0.89 | CFTR (0.72) | CFTRKDM4EMEN1KMT2ALMNA | |
| SCHEMBL10475864 | 0.86 | CFTR (0.52) | CFTRCASRPOLBKDM4EMEN1 | |
| SCHEMBL28381810 | 0.81 | CFTR (0.56) | CFTRKDM4EMEN1KMT2ALMNA | |
| SCHEMBL6514222 | 0.80 | ALDH1A1 (0.59) | CFTRPOLBKDM4EMEN1KMT2A | |
| SCHEMBL29411968 | 0.80 | ALDH1A1 (0.64) | CFTRCASRKDM4EMEN1KMT2A | |
| SCHEMBL28484825 | 0.80 | ALDH1A1 (0.64) | CFTRCASRKDM4EMEN1KMT2A | |
| SCHEMBL28901986 | 0.79 | MEN1 (0.58) | CASRPOLBKDM4EMEN1KMT2A | |
| SCHEMBL29412050 | 0.79 | MEN1 (0.58) | CASRPOLBKDM4EMEN1KMT2A | |
| SCHEMBL6514322 | 0.79 | ALDH1A1 (0.62) | CFTRPOLBKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978301-B | Benzimidazole compound with endothelial lipase inhibition effect and application thereof | 盐城师范学院 | 2022-08-02 | — | — | CN | disclosed |
| CN-111978301-A | Benzimidazole compound with endothelial lipase inhibition effect and application thereof | 盐城师范学院 | 2020-11-24 | — | — | CN | disclosed |
| EP-2479282-B1 | Media including nitroreductase enzymatic substrates | BIOMERIEUX SA (FR) | 2018-03-28 | — | — | EP | disclosed |
| EP-2155893-B1 | NOVEL NITROREDUCTASE ENZYMATIC SUBSTRATES | BIOMERIEUX SA (FR) | 2016-10-19 | — | — | EP | disclosed |
| EP-2471944-B1 | Novel peptidase substrates | BIOMERIEUX SA (FR) | 2016-09-14 | — | — | EP | disclosed |
| EP-2155892-B1 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2479282-A1 | Media including nitroreductase enzymatic substrates | bioMérieux (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8216800-B2 | Substrates for detecting peptidase activity and methods using the substrates | BIOMERIEUX (FR) | 2012-07-10 | — | — | US | disclosed |
| EP-2471944-A1 | Novel peptidase substrates | bioMérieux (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20100099128-A1 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2155892-A2 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008152306-A2 | NOVEL PEPTIDASE SUBSTRATES | bioMérieux (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099128-A1 | NOVEL PEPTIDASE SUBSTRATES | XPNPEP1, DPEP1, DDAH1 | CFTR 2032/4885CASR 959/4885POLB 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.